335例心脑血管病患者阿司匹林抵抗与环氧化酶2基因多态性位点的相关性

目的探讨心脑血管病患者环氧化酶2(COX-2)基因单核苷酸多态性(SNP)位点-1195G>A和-765G>C与阿司匹林抵抗(AR)的相关性。方法纳入中国北方汉族冠心病及缺血性脑卒中患者335例,根据血小板聚集率分为AR组27例、阿司匹林半抵抗(ASR)组68例和阿司匹林敏感(AS)组240例。SNP检测采用实时荧光定量PCR方法,使用SHEsis软件构建单体型。并进行分析。结果 AS组、ASR和AR组-1195G>A位点的GG、GA、AA分布频率比较,差异有统计学意义(P=0.003);3组-1195G>A位点隐性模型GA+AA和GG基因型分布频率亦存在统计学差异(P<0.01),3组等位基因A分布频率比较,差异有统计学意义(P=0.009)。3组-765G>C位点基因型、等位基因型分布频率比较,差异无统计学意义(P=0.822)。AS组与ASR组、AS组与AR组单体型G-G和A-G分布频率均存在统计学差异(P<0.05,P<0.01)。相关因素校正后,logistic回归分析显示,COX-2的-1195G>A GA+AA基因型仍与AR和ASR的发生显著相关(OR=3.381,95%CI:1.439～7.944)。结论 COX-2基因的-1195G>A等位基因A可能与AR及ASR的发生具有关联性,可能是AR及ASR发生的一个遗传易感性标记位点。     

环氧合酶-2基因启动子区单核苷酸多态性与非酒精性脂肪肝遗传易感性的关系

目的 通过检测环氧合酶-2(COX-2)基因启动子区单核苷酸的多态性,以探讨其与非酒精性脂肪肝(NAFLD)遗传易感性的关系.方法 对200例NAFLD患者和206名正常对照,采用多聚酶链反应-限制性片段长度多态性(PCR-RFLP)方法对COX-2基因启动子区-765G＞C和-1195G＞A多态性进行基因型分析.计量资料结果用均数±标准差((-x)±s)表示,经方差齐性检验后,行t检验;性别、基因型及等位基因频率的比较行x2检验.结果 正常对照中,COX-2基因启动子区-765G＞C和-1195G＞A等位基因的分布频率分别为48%和2%,NAFLD患者组二者分别为54%和5%.多变量Logistic回归分析显示:-765GC基因携带者与-765GG基因携带者相比较,前者发生NAFLD的比值比(OR)=2.35 (95% CI为1.17～3.65);-1195AA基因携带者与-1195GG基因携带者相比较,前者发生NAFLD的OR=1.13 (95% CI为1.01～2.46).与单体型G-1195-G765相比较,含有A1195的A-1195-C-765、A1195-G765两种单体型发生NAFLD的相对风险明显升高,OR分别为1.42 (95% CI为1.11～1.63,P＜0.05)和4.24(95% CI为1.72～14.22,P＜0.01).且A-1195-C765发生NAFLD的OR值高于A-1195-G-765、G-1195-C765的单体型.这一结果提示在同一单体型内-1195A与-765C之间存在交互作用.结论 COX-2基因启动子区的-1195G＞A和-765G＞C单核苷酸存在多态性,与NAFLD发生相关,是决定NAFLD个体遗传易感性的重要因素.     

环氧化酶-2基因-765G>C多态性与老年代谢综合征患者阿司匹林抵抗无关

目的探讨老年代谢综合征患者阿司匹林抵抗的罹患率及其与环氧化酶-2(COX-2)基因-765G>C多态性的关系。方法 106位老年代谢综合征患者口服阿司匹林100mg/d至少20天,根据Chrono-log560CA全血发光血小板聚集系统检测结果分为阿司匹林抵抗(AR)组或阿司匹林敏感(AS)组,然后应用聚合酶链反应和限制性片段长度多态性(PCR-RFLP)技术分析COX-2基因-765G>C多态性。结果老年代谢综合征患者中阿司匹林抵抗的罹患率为31.13%,-765G>C多态性三种基因型GG、GC和CC的分布频率分别为68.9%、22.6%和8.5%,-765C等位基因分布频率为19.8%。AR和AS两组患者-765G>C多态性的基因型(p=0.553)和等位基因(p=0.714)分布频率没有显著差异。结论 COX-2基因-765G>C多态性与老年代谢综合征患者阿司匹林抵抗无关。     

COX-2基因多态性与结直肠癌发病风险的关系研究

目的 探讨环氧合酶-2(COX-2)-765G＞C、-1195G＞A、8473T＞C基因多态性与结直肠癌(CRC)遗传易感性的关系,同时评估COX-2基因多态性与某些因素共同作用对CRC发病风险的影响.方法 采用病例对照研究方法,入选CRC患者130例及健康非肿瘤人群120例.PCR-RFLP方法检测病例组和对照组COX-2基因的3个多态基因型,结果采用非条件logistic回归分析,用比值比(OR)及95％可信区间(CI)评估研究因素对疾病危险度的作用.结果 病例组COX-2-765G＞C、-1195G＞A、8473T＞C基因型频率与对照组间的差异均无统计学意义.根据体重指数(BMI)将研究对象分层后,发现-765GG基因型与CRC发病风险的相关性具有统计学意义,与正常BMI(＜23)相比,携带-765GG基因型且超重或肥胖者(BMI≥23)患CRC风险增高(OR=2.024,95％CI:1.089～3.760,P=0.024).此外,还发现吸烟可增加患CRC的风险,与不吸烟人群相比,吸烟人群中的8473TT基因型携带者患CRC的风险明显增高(OR=1.938,95％CI:1.021～3.677,P=0.042).结论 虽然COX-2 765G＞C、-1195G＞A、8473T＞C基因多态性与CRC遗传易感性之间没有相关性,但是携带-765GG基因型的高BMI人群或携带8473TT基因型的吸烟人群的CRC发生风险显著增高.对COX-2基因多态性位点的检测将有助于预防CRC的发生.     

COX-2基因单核苷酸多态性与结直肠腺瘤遗传易感性的关系

目的 探讨环氧合酶-2(COX-2)基因多态性与结直肠腺瘤(CRA)易感性的关系.方法 采用病例对照研究方法,应用聚合酶链反应-限制性片段长度多态性技术(PCR-RFLP)和错配聚合酶链反应-限制性片段长度多态性技术(PIRA-PCR),分别检测110例CRA患者和120名健康人群的COX-2基因-765G＞C、-1195G＞A、8473T＞C 3个多态位点,采用x2检验比较不同基因型与CRA易感性的关系.结果 CRA组和对照组的COX-2-765 G＞C、-1195G＞A 2个位点的3种基因型频率分布差异无统计学意义(P=0.972,P=0.313);两组间COX-2 8473T＞C位点的3种基因型分布差异有统计学意义(P=0.034),Logistic回归分析显示,携带突变等位基因C的个体(8473TC+CC) CRA的易感性显著降低(OR=0.500,95 ％CI:0.274-0.913,P=0.024).结论 COX-2-765G＞C、-1195G＞A可能与CRA易感性无关,COX-2 8473T＞C与CRA易感性相关.     

环氧化酶-2基因多态性与回族人群胃癌易感性的关联

目的: 探讨环氧化酶-2(COX-2)-765G>C的单核昔酸多态性与回族人群胃癌易感性的关系.方法: 以PCR-限制性片段长度多态性方法对回族人群中胃癌组( n = 100)、癌前病变组( n =102)和正常对照组( n = 105)进行基因分型. 使用ELISA法检测H pylori感染.结果: COX-2-765GC+CC在胃癌组显著增高( P = 0.021). 交互作用分析显示: 食腌菜的-765GC+CC携带者患胃癌的风险是不食腌菜的-765GG携带者的5.038倍( P = 0.000);H pylori感染阳性的-765GC+CC携带者患胃癌的风险是H pylori感染阴性-765 GG携带者的3.520倍( P = 0.002).结论: COX-2-765G>C和中国甘肃地区回族人群胃癌易感性增高相关. -765 GC+CC分别与食腌菜、H pylori感染在胃癌的发病风险中存在着加乘交互效应.     

COX-2基因多态性及H pylori感染与胃癌高发区甘肃河西地区胃癌的相关性

目的:研究COX-2-899G>C,COX-2codon 587G>A基因多态性在胃癌高发区甘肃河西地区健康人群与胃癌患者的分布,检测幽门螺旋杆(Hpylori)在上述人群中的感染情况,探讨COX-2-899G>C,COX-2codon587G>A基因多态性以及H pylori感染与河西地区胃癌发生的关系.方法:采用PCR-TaqMan探针法检测甘肃河西地区健康人群和胃癌患者COX-2-899G>C,COX-2codon 587G>A的基因多态性,用Warhin-starry染色法检测本研究对象的Hpylori感染率.结果:COX-2-899G>C分为G/G,G/C,C/C三种基因型,其频率在胃癌患者中分别为72.9％,21.4％,5.7％;在普通人群中分别为84.0％,12.8％,3.2％.与G/G基因型相比,COX-2-899*C基因携带者患胃癌的风险增加(OR=1.956,95％CI:1.067-3.586).COX-2codon587G>A三种基因型为G/G,G/A,A/A,其频率在胃癌患者中分别为86.4％,11.4％,2.2％;在健康人群中分别为89.6％,9.6％,0.8％.COX-2eodon 587G>A三种基因型在胃癌组和健康对照组间无显著性差别.Hpylori感染率在胃癌组和对照组分别为68.6％,50.4％,两组间具有显著差异(P=0.003).分层分析提示COX-2-899*C基因携带者若同时伴有Hpylori感染,其患胃癌的风险明显增加(OR=2.471,95％CI:1.076-5.675).结论:COX-2-899G>C的C等位基因增加我国胃癌高发区甘肃河西地区胃癌发病的风险,而且与H pylori感染对胃癌的发病有一定的协同作用;Cox-2 codon 587G>A基因多态性与甘肃河西地区胃癌的易感性无关.     

环氧化酶-2基因启动子区多态性与结直肠癌的易感性

目的:探讨环氧化酶-2(cyclooxygenase-2,COX-2)基因启动子区的-1195(G/A,rs689466)及3’非翻译区的8473(T/C,rs5275)2个位点的基因多态性与结直肠癌(colorectal cancer,CRC)发病风险的相关性.方法:采用病例-对照研究,利用聚合酶链式反应和限制性片段长度多态性(polymerase chain reaction-restrictive fragment length polymorphism,PCR-RFLP)分析方法,对343例CRC患者和340例健康人的COX-2基因的2个位点的多态性进行检测,采用SPSS11.0软件包统计分析各位点的基因型分布和等位基因频率.结果:COX-2-8473位点多态性的各基因型频率在病例组及对照组中分布均无显著差异(P>0.05),但COX-2-1195位点多态性的基因型频率在二组中分布有显著性差异(P<0.001),结果显示CRC患者COX-2-1195AG基因型在病例组的频率较对照组显著增高(校正后OR=2.23;95%CI:1.50-3.32),AA基因型在病例组中的频率亦较对照组高(校正后OR=2.46;95%CI:1.51-4.02),A等位基因携带者在病例组中的频率高于对照组(校正后OR=2.27;95%CI:1.55-3.34).各基因型分布在结肠癌及直肠癌中的分布无显著性差异(P>0.05).COX-2-1195A等位基因与淋巴结转移及TNM分期有显著相关性.结论:COX-2-1195位点AG/AA基因型是CRC的风险因素,且与CRC的淋巴结转移及TNM分期相关.     

缺血性脑卒中患者环氧化酶-1、-2基因多态性与阿司匹林抵抗的关系

目的探讨环氧化酶(COX)的基因多态性与阿司匹林抵抗(AR)的关系。方法选取缺血性脑卒中(IS)患者300例,依据血小板聚集率分为阿司匹林敏感组(AS组,180例)、阿司匹林半抵抗组(ASR组,84例)和AR组(36例);比较3组一般临床资料,采用光比浊法检测血小板聚集率。应用聚合酶链反应(PCR)和限制性片段长度多态性(RFLP)技术检测COX基因多态性,并比较两组基因型和等位基因分布差异。结果 AR组与ASR组COX-1上A-842/C50T有统计学差异(P<0.05),而COX-2-765G>C(rs20417)无统计学差异(P>0.05)。结论 COX-1上的T等位基因是其突变基因,C/T和TT突变会增加AR的风险,而COX-2-765G>C的基因突变与AR无相关性。     

海南籍黎族和汉族急性脑梗死患者C反应蛋白和白细胞介素18的基因多态性研究

目的探讨C反应蛋白(CRP)-1059 G/C,白细胞介素18(IL-18)启动子基因-607 C/A和-137 G/C位点的基因多态性与海南黎、汉族人群急性脑梗死的相关性。方法选择汉族脑梗死患者115例为汉族脑梗死组和黎族脑梗死患者52例为黎族脑梗死组,分别与健康的汉族对照组116例和黎族对照组51例对照研究。测定CRP-1059 G/C、IL-18启动子基因-607 C/A和-137 G/C位点基因多态性。结果汉族脑梗死组CRP-1059 G/C位点C等位基因频率与汉族对照组比较,差异有统计学意义(P=0. 044),并且CRP-1059 G/C位点GG+GC基因型频率明显高于汉族对照组,CC基因型明显低于汉族对照组(78. 3%vs 87. 9%),差异有统计学意义(P=0. 049)。黎族脑梗死组CRP-1059 G/C、IL-18-607 C/A及IL-18-137 G/C位点的基因型和等位基因频率与黎族对照组比较,差异无统计学意义(P 0. 05)。多因素logistic回归分析显示,CRP-1059 GG+GC基因型为汉族脑梗死患者的独立危险因素(P 0. 05)。结论 CRP-1059 GG+GC基因型是海南籍汉族脑梗死患者的独立危险因素。而IL-18-607 C/A、IL-18-137 G/C基因多态性均与海南籍黎、汉族脑梗死患者无关。     

Role of cyclooxygenase-2 gene polymorphisms in pancreatic carcinogenesis

AIM:To evaluate the clinical significance of-765G/C and-1195G/A cyclooxygenase-2 (COX-2) gene polymorphisms in patients with pancreatic cancer (PC).METHODS:The study included 201 patients:85 with PC and 116 healthy controls.-765G/C and-1195G/A COX-2 gene polymorphisms were studied in DNA isolated from blood samples.The associations of the analyzed genotypes and clinical data at diagnosis were evaluated.RESULTS:We found an increased frequency of the homozygous-1195AA COX-2 genotype in patients with PC (53.7%...     

COX-2 polymorphisms -765G →C and -1195A→G and colorectal cancer risk

AIM： TO determine the possible modulating effect of the COX-2 polymorphisms, -765G→C and -1195A→G, on the risk of colorectal cancer （CRC） in a Dutch population. METHODS： This case-control study includes 326 patients with CRC and 369 age- and gender-matched controls. Genotypes of the COX-2 polymorphisms -7dEG→C and -1195A→G were determined by polymerase chain reaction-based restriction fragment length polymorphism. COX-2 genotypes and haplotypes were analyzed and odds ratios with 95% confidence intervals were estimated by logistic regression. RESULTS： The -765GG genotype was associated with an increased risk of developing CRC （OR, 1.45; 95% CI, 1.03-2.04）. No significant difference was observed in the genotype distribution of the -1195A→G polymorphism between patients and controls. The GG/AC haplotype was present significantly less often in patients than in controls （OR 0.44; 95% CI, 0.22-0.85）. When the AC, AG and GG haplotypes were investigated separately, the AC haplotype showed a tendency to be less frequent in patients than in controls （OR（AG/AC） 0.78; 95% CI, 0.57-1.06）. CONCLUSION： The -765GG genotype is associated with an increased risk of developing CRC and the G6/ AC haplotype seems to protect against CRC. These findings suggest a modulating role for the COX-2 polymorphisms -765G→C and -1195A→G in the development of CRC in a Dutch population.     

The COX-2 G/C -765 polymorphism may modulate the occurrence of cerebrovascular ischemia.

In the atherosclerotic plaque, cyclooxygenase-2 (COX-2) catalyzes prostaglandin E formation, which acts as a pro-atherogenic factor. A polymorphism, G/C -765, within the COX-2 promoter region modulates gene expression and the risk of cerebrovascular disease. We have evaluated the relation between COX-2 G/C -765 genotypes and the occurrence of cerebrovascular ischemia. We evaluated the COX-2 G/C -765 polymorphism in 110 consecutive patients with a documented history of acute ischemic cerebrovascular disease, in 110 age-matched and sex-matched subjects without such history, and in a general population (n = 324) from the same ethnical background. The frequency of the COX-2 -765C allele in patients [0.21; 95% confidence interval (CI), 0.16-0.26] was similar to those found in controls (0.28; 95% CI, 0.22-0.34) and in the general population (0.26; 95% CI, 0.23-0.29). Carriers of the CC genotype differed between patients (0.02; 95% CI, 0.00-0.05) and controls [0.10 (95% CI, 0.04-0.16), P = 0.019; odds ratio, 0.17 (95% CI, 0.04-0.79)] or the general population [0.08 (95% CI, 0.05-0.11), P = 0.023; odds ratio, 0.22 (95% CI, 0.05-0.95)]. In a multiple logistic regression analysis adjusted for confounding variables, smoking status (P < 0.001), atrial fibrillation (P = 0.004) and COX-2 G/C-765 polymorphism (P = 0.016) independently contributed to cerebrovascular ischemia, with CC carriers exhibiting a lower risk (odds ratio, 0.07; 95% CI, 0.01-0.61). Our data show an association between the COX-2 G/C-765 gene polymorphism and cerebrovascular ischemia, suggesting that the COX-2 gene is a susceptibility locus for the risk of cerebrovascular ischemic disease.     

Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno- or squamous cell carcinoma

AIM： TO determine whether -1195 A→G and/or -765 G→C polymorphisms in Cyclooxygenase-2 CCOX-2） may have a risk modifying effect on the development of esophageal carcinoma in a Dutch Caucasian population. METHODS： Two study groups were recruited, 252 patients with esophageal carcinoma and 240 healthy controls, matched for race, age, gender and recruiting area. DNA was isolated from whole blood and used for genotyping. PCR products were digested with restriction enzymes and products were analyzed by agarose gel electrophoresis. Odds ratios （OR） and 95% confidence intervals （CI） were estimated. RESULTS： The distribution of the -1195A→G polymorphism was significantly different in esophageal cancer patients compared to controls. The -1195 GG genotype resulted in a higher risk of developing esophageal adenocarcinoma （OR = 3.85, 95% CI： 1.45-10.3） compared with the -1195AA genotype as a reference. The -765 G→C genotype distribution was not different between the two groups. The GG/ GG haplotype was present more often in esophageal adenocarcinoma patients than in controls （OR = 3.45, 95% CI： 1.24-9.58; with AG/AG as a reference）. The same trends were observed in patients with squamous cell carcinomas, however, the results did not reach statistical significance. CONCLUSION： Presence of the COX-2 -1195 GG genotype and of the GG/GG haplotype may result in a higher risk of developing esophageal carcinoma.     

Association between COX-2-1195G>A polymorphism and gastrointestinal cancer risk: A meta-analysis

AIM To perform a meta-analysis to investigate the association between cyclooxygenase-2(COX-2)-1195GA gene polymorphism and gastrointestinal cancers. METHODS Publications related to the COX-2-1195GA gene polymorphism and gastrointestinal cancers published before July 2016 were retrieved from Pub Med, EMBASE, Web of Science, China Biological Medicine Database, China National Knowledge Infrastructure, and CQVIP Database. Meta-analysis was performed using Stata11.0 software. The strength of the association was evaluated by calculating the combined odds ratios(ORs) and the corresponding 95%CIs. The retrieved publications were excluded or included one by one for sensitivity analysis. In addition, the funnel plot, Begg's rank correlation test, and Egger's linear regression method were applied to analyse whether the included publications had publication bias. RESULTS A total of 24 publications related to the COX-2-1195GA gene polymorphism were included, including 28 studies involving 11043 cases and 18008 controls. The meta-analysis results showed that the COX-2-1195GA gene polymorphism significantly correlated with an increased risk of gastrointestinal cancers, particularly gastric cancer(A vs G: OR = 1.35; AA/AG vs GG: OR = 1.54; AA vs GG/AG: OR = 1.43; AA vs GG: OR = 1.80; AG vs GG: OR = 1.35). Compared to the Caucasian population in America and Europe, the COX-2-1195GA gene polymorphism in the Asian population(A vs G: OR = 1.30; AA/AG vs GG: OR= 1.50; AA vs GG/AG: OR = 1.35; AA vs GG: OR = 1.71; AG vs GG: OR = 1.37) significantly increased gastrointestinal cancer risk. The sensitivity analysis(P 0.05) and the false positive report probability(P 0.2) confirmed the reliability of the results. CONCLUSION The results showed that the COX-2-1195GA gene polymorphism might be a potential risk factor for gastrointestinal cancers. Further validation by a large homogeneous study is warranted.     

COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma

BACKGROUND: Neoplastic progression of BE towards EAC is associated with increased expression of COX-2. Increased COX-2 expression and enzyme activity is linked to the COX-2 CA haplotype, which consists of two gene polymorphisms in the COX-2 promoter. AIM: To study the impact of COX-2 haplotypes on the risk of developing EAC in patients with different forms of gastroesophageal reflux disease including BE. METHODS: DNA was obtained from a total of 635 Dutch white patients comprised of 140 patients with EAC, 255 with BE, and 240 with reflux esophagitis. COX-2 haplotypes were based on the gene polymorphisms at -765C/G and -1195A/G, as determined by PCR-RFLP. RESULTS: The tested population contained 170 (14%) CA- (-765C and -1195A) haplotypes, 829 (65%) GA and 271 (21%) GG-haplotypes, and no GC-haplotypes. The haplotype distribution in patients with reflux esophagitis and BE was similar (CA 12%, GA 68%, GG 21%), but differed significantly from that in patients with EAC (CA 21%, GA 58%, GG 20%). Particularly, the CA-haplotype was more common (P < 0.001) in EAC patients. CA-carriership was associated with EAC (OR 2.8, 95% CI 1.3-6.2, P= 0.008), with homozygosity for the CA-allele being statistically most significantly associated (OR 6.1, 95% CI 1.6-24.2, P= 0.01). CONCLUSION: The COX-2 CA-haplotype is more frequently observed in patients with EAC than in patients with BE and reflux esophagitis. These data suggest a direct link between COX-2 activity and neoplastic progression in patients with BE and reflux esophagitis.     

Potentially functional COX‐2 −1195G>A polymorphism increases the risk of digestive system cancers: A meta‐analysis

Background and Aim: Three potentially functional polymorphisms: ?765G>C, ?1195G>A, and 8473T>C in the cyclooxygenase‐2 (COX‐2) gene were identified and proposed to be associated with cancer susceptibility. The aim of this meta‐analysis was to evaluate the association between these three polymorphisms and the risk of cancer in diverse populations. Methods: All case‐control studies published up to November 2009 on the association between the three polymorphisms of COX‐2 and cancer risk were identified by searching PubMed. The cancer risk associated with the three polymorphisms of the COX‐2 gene was estimated for each study by OR together with its 95% confidence interval (CI), respectively. Results: A total of 47 case‐control studies were included, and variant genotypes GA/AA of ?1195G>A were associated with a significantly increased cancer risk (GA/AA vs GG: odds ratio [OR], 1.29; 95% CI, 1.18–1.41; P_{heterogeneity} = 0.113), and this significant association was mainly observed within cancers of the digestive system (e.g. colorectal, gastric, esophageal, oral, biliary tract, gallbladder, and pancreatic) without between‐study heterogeneity (GA/AA vs GG: OR, 1.36; 95% CI; 1.23–1.51; P_{heterogeneity} = 0.149). Furthermore, a stratification analysis showed that the risk of COX‐2?1195G>A associated with cancers in the digestive system was more evident among Asians than Caucasians. However, for COX‐2?765G>C and 8473T>C, no convincing association between the two polymorphisms and risk of cancer or cancer type was observed. Conclusions: The effect of three potentially functional polymorphisms (?765G>C, ?1195G>A, and 8473T>C) in the COX‐2 gene on cancer risk provided evidence that the COX‐2?1195G>A polymorphism was significantly associated with increased risk of digestive system cancers, especially among Asian populations.     

RAGE基因-374T/A多态性与中国汉族人群冠状动脉粥样硬化性心脏病的相关性研究

目的观察晚期糖基化终产物受体(receptor of advanced glycation end products,RAGE)基因启动区-374T/A多态性在中国汉人冠状动脉粥样硬化性心脏病(冠心病)人群和对照组人群中的分布特点,并比较两者之间的差异,分析RAGE基因启动区-374T/A多态性与冠心病的相关性。方法应用Tsp509 I限制性内切酶的多聚酶链反应-限制性片断长度多态性(PCR-RFLP)法,检测127例冠心病患者和88例对照组人群的RAGE多态性基因型。结果冠心病组与对照组间RAGE基因-374T/A多态性等位基因频率和基因型频率比较,差异均无统计学意义(P0.05);单因素logistic回归分析提示,AA基因型与冠心病无关联[OR=0.201,95%CI(0.201,4.220),P=0.9 155]。亚组分析显示,非糖尿病冠心病组与非糖尿病对照组RAGE基因-374T/A多态性等位基因频率和基因型频率比较,差异均无统计学意义(P0.05);单因素logistic回归分析提示,AA基因型与非糖尿病冠心病无关联[OR=1.415,95%CI(0.253,7.926),P=0.6 929]。结论 RAGE基因启动区-374T/A多态性可能与中国汉人冠心病的易感性无关联,其AA基因型可能不是中国汉人冠心病的保护因素。